Small-Molecule Allosteric Activators of Sirtuins
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
MetadataShow full item record
CitationSinclair, David A., and Leonard Guarente. 2014. “Small-Molecule Allosteric Activators of Sirtuins.” Annual Review of Pharmacology and Toxicology 54 (1) (January 6): 363–380. doi:10.1146/annurev-pharmtox-010611-134657.
AbstractThe mammalian sirtuins (SIRT1-7) are NAD(+)-dependent lysine deacylases that play central roles in cell survival, inflammation, energy metabolism, and aging. Members of this family of enzymes are considered promising pharmaceutical targets for the treatment of age-related diseases including cancer, type 2 diabetes, inflammatory disorders, and Alzheimer's disease. SIRT1-activating compounds (STACs), which have been identified from a variety of chemical classes, provide health benefits in animal disease models. Recent data point to a common mechanism of allosteric activation by natural and synthetic STACs that involves the binding of STACs to a conserved N-terminal domain in SIRT1. Compared with polyphenols such as resveratrol, the synthetic STACs show greater potency, solubility, and target selectivity. Although considerable progress has been made regarding SIRT1 allosteric activation, key questions remain, including how the molecular contacts facilitate SIRT1 activation, whether other sirtuin family members will be amenable to activation, and whether STACs will ultimately prove safe and efficacious in humans.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34865300
- HMS Scholarly Articles